Table 4.

HCC risks in relation to HBV mutations and AFB₁ exposure in cases and controls.

BCP Mutations	AFB1-lysine adduct	Controls (%)	Cases (%)	OR (95% CI)	Adjusted OR (95%CI)*
1762T/1764A double mutations or 1762T single mutations	Concentration (pgrfmg alb.)
No	<6.46	22(18.3)	3 (5.0)	1.00	1.00
	≥6.46	9 (7.5)	2 (3.3)	1.63 (0.23–11.45)	2.01 (0.24–14.49)
Yes	<6.46	66 (55.0)	36 (60.0)**	4.00(1.12–14.27)	4.26 (1.16–15.38)
	≥6.46	23(19.2)	19(31.7)**	6.06(1.57–23.37)	6.94 (1.68–27.78)
1752V mutations	Concentration (pg/mg alb.)
No	<6.46	65 (54.2)	21(35.0)	1.00	1.00
	≥6.46	24 (20.0)	9 (15.0)	1.16(0.47–2.89)	1.20 (0.47–3.08)
Yes	<6.46	23(19.2)	18(30.0)**	2.42(1.10–5.33)	2.28(1.01–5.31)
	≥6.46	8 (6.7)	12(20.0)**	4.65(1.67–12.89)	5.13 (1.79–14.71)

^*adjusted for age, gender, first-degree family history of cancer

^**p <0.05 from unconditional logistic regression in comparison with baseline group (no mutation and lower than average AFB₁-lysin adduct)